Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Journal of Hepatology|January 18, 2015
Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4Christophe Moreno, Christophe Hezode, Patrick Marcellin, et al.
Antiviral Therapy|April 29, 2022
Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adultsEdward Gane, Mina Pastagia, Ullrich Schwertschlag, et al.
NPJ Vaccines|February 5, 2026
Safety, immunogenicity, and baseline immune correlates of vaccine JNJ-0535 in participants with or without CHBSimon Verheijden, Nádia Conceição-Neto, Stefan Bourgeois, et al.
Hepatology (Baltimore, Md.)|January 23, 2016
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized studyPaul Kwo, Norman Gitlin, Ronald Nahass, et al.
BMC Infectious Diseases|June 4, 2017
Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover studyEdward J Gane, Edwin DeJesus, Ewa Janczewska, et al.
Hepatology (Baltimore, Md.)|December 26, 2015
Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)Eric Lawitz, Gary Matusow, Edwin DeJesus, et al.
Hepatology (Baltimore, Md.)|January 30, 2019
JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1Stefan Zeuzem, Stefan Bourgeois, Susan Greenbloom, et al.
Lancet (London, England)|August 1, 2014
Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised studyEric Lawitz, Mark S Sulkowski, Reem Ghalib, et al.
Pageof 2